Filament Health and PharmAla Biotech Holdings Inc. have announced the GMP release of MDMA capsules at a Metro Vancouver facility operated by Filament’s subsidiary Psilo Scientific.
Filament and PharmAla have entered into a partnership which will see Filament’s subsidiary Psilo Scientific was contracted to manufacture MDMA capsules for PharmAla.
It will do this by utilising PharmAla’s previously-manufactured GMP LaNeo™ MDMA Active Pharmaceutical Ingredient (API).
The capsules are will be distributed to clinical trial customers and authorised patients in Canada and globally. The MDMA was encapsulated at Psilo Scientific’s GMP-compliant, Health Canada-licensed facility.
CEO and Co-Founder of Filament Health, Benjamin Lightburn, commented: “The GMP release of MDMA drug product is an exciting step for the psychedelic industry, and indicative of our manufacturing capability.
“MDMA has shown promise for treating a range of health conditions and we’re proud to support PharmAla’s efforts to improve access.”
“PharmAla has been working for some time to fill the backlog of MDMA for clinical researchers all over the world. As the psychedelics industry matures, the amount of clinical research for MDMA is set to grow,” added Nick Kadysh, CEO at PharmAla Biotech.
“We’re happy to have reached this important milestone which will allow Pharmala to further distribute finished MDMA drug product to qualified researchers, and are grateful to Filament for their partnership.
“Our eyes are now fully set on jurisdictions like Australia, which will require full commercial-scale manufacturing of both GMP API and drug product to fulfill demand for patients -and those jurisdictions still to come.”
